Advertisement

Topics

US FDA Panel Weighs Design Of A Pre-approval Safety Study For Janssen's Sirukumab

12:12 EDT 8 Aug 2017 | SCRIP

IL-6 inhibitor should be compared to another biologic to exclude a multi-fold increase in the risk of death, advisers say;...

      

Related Stories

 

Original Article: US FDA Panel Weighs Design Of A Pre-approval Safety Study For Janssen's Sirukumab

NEXT ARTICLE

More From BioPortfolio on "US FDA Panel Weighs Design Of A Pre-approval Safety Study For Janssen's Sirukumab"

Quick Search
Advertisement